Correlation analyses of PRO endpoints at month 3
| HAQ-DI | SF-36v2† PF | SF-36v2† BP | Pain-VAS | EQ-5D-3L P/D | |
| Tofacitinib 5 mg twice daily (N=101) | |||||
| HAQ-DI | 1 | −0.67 | −0.61 | 0.55 | 0.33 |
| SF-36v2† PF | – | 1 | 0.64 | −0.56 | −0.38 |
| SF-36v2† BP | – | – | 1 | −0.70 | −0.50 |
| Pain-VAS | – | – | – | 1 | 0.42 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
| Tofacitinib 10 mg twice daily (N=103) | |||||
| HAQ-DI | 1 | −0.85 | −0.68 | 0.58 | 0.46 |
| SF-36v2† PF | – | 1 | 0.68 | −0.52 | −0.43 |
| SF-36v2† BP | – | – | 1 | −0.65 | −0.60 |
| Pain-VAS | – | – | – | 1 | 0.42 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
| Adalimumab 40 mg subcutaneous injection once every 2 weeks (N=100) | |||||
| HAQ-DI | 1 | −0.83 | −0.71 | 0.67 | 0.53 |
| SF-36v2† PF | – | 1 | 0.74 | −0.63 | −0.61 |
| SF-36v2† BP | – | – | 1 | −0.74 | −0.70 |
| Pain-VAS | – | – | – | 1 | 0.58 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
| Placebo (N=102) | |||||
| HAQ-DI | 1 | −0.76 | −0.66 | 0.58 | 0.36 |
| SF-36v2† PF | – | 1 | 0.72 | −0.57 | −0.44 |
| SF-36v2† BP | – | – | 1 | −0.58 | −0.39 |
| Pain-VAS | – | – | – | 1 | 0.34 |
| EQ-5D-3L P/D | – | – | – | – | 1 |
All correlations were **p<0.01, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the analysis included patients with observations at a visit of interest in the Full Analysis Set; N is the number of patients included in calculating the sample correlation.
†SF‑36v2 scores are norm-based.
BID, twice daily; BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions 3-level questionnaire; HAQ‑DI, Health Assessment Questionnaire Disability Index; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.